Drug Trial Radar · NCT06573008
Study of GP681 Tablets Compared With Placebo in Patients With Influenza at High Risk of Influenza Complications
Last checked: Nov 19, 2026Latest source record: Dec 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
328
Planned (sponsor's estimate)
Start
Nov 11, 2024
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 27, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy, safety, and population pharmacokinetics of a single, oral dose of GP681 compared with placebo in patients aged 12 and older With Influenza at High Risk of Influenza Complications.
Conditions
- Influenza, Human
Interventions
GP681 40mgDrug
2 x 20mg tablets taken orally
GP681 SimulantDrug
Placebo tablets matching GP681 40mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to alleviation of influenza symptomsTime frame: up to Day 15
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The people's Hospital of Chizhou
Chizhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.